NCT06762977View on ClinicalTrials.gov

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

RecruitingOBSERVATIONAL
Enrollment

180

Participants

Timeline

Start Date

November 13, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2026

Conditions
Breast Cancer Early Stage Breast Cancer (Stage 1-3)HER2
Trial Locations (2)

72100

RECRUITING

Ospedale Di Summa-Perrino, Brindisi

80131

RECRUITING

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Naples

All Listed Sponsors
collaborator

Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

NETWORK

collaborator

Ospedale Di Summa-Perrino

UNKNOWN

lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER